Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
318 results about "White blood cell number" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The number of leukocytes in the blood is often an indicator of disease, and thus the WBC count is an important subset of the complete blood count. The normal white cell count is usually between 4 × 109/L and 1.1 × 1010/L. In the US, this is usually expressed as 4,000 to 11,000 white blood cells per microliter of blood.
Phage antibodies
Peripheral blood leucocytes incubated with a semi-synthetic phage antibody library and fluorochrome-labeled CD3 and CD20 antibodies were used to isolate human single chain Fv antibodies specific for subsets of blood leucocytes by flow cytometry. Isolated phage antibodies showed exclusive binding to the subpopulation used for selection or displayed additional binding to a restricted population of other cells in the mixture. At least two phage antibodies appeared to display hithereto unknown staining patterns of B lineage cells. This approach provides a subtractive procedure to rapidly obtain human antibodies against known and novel surface antigens in their native configuration, expressed on phenotypically defined subpopulations of cells. Importantly, this approach does not depend on immunization procedures or the necessity to repeatedly construct phage antibody libraries.
Owner:JANSSEN VACCINES & PREVENTION BV
Method and apparatus for reflected imaging analysis
InactiveUS6104939AQuick measurementPolarisation-affecting propertiesScattering properties measurementsWhite blood cellPolarizer
Method and apparatus for reflected imaging analysis. Reflected imaging is used to perform non-invasive, in vivo analysis of a subject's vascular system. A raw reflected image (110) is normalized with respect to the background to form a corrected reflected image (120). An analysis image (130) is segmented from the corrected reflected image to include a scene of interest for analysis. The method and apparatus can be used to determine such characteristics as the hemoglobin concentration per unit volume of blood, the number of white blood cells per unit volume of blood, a mean cell volume, the number of platelets per unit volume of blood, and the hematocrit. Cross-polarizers can be used to improve visualization of the reflected image.
Owner:INTPROP MVM
Methods of treatment of disease using adsorbent carriers
InactiveUS6498007B1Increase productionReduce in quantityAntibacterial agentsSolvent extractionDiseaseAcetic acid
The invention relates to a method for the removal of leucocytes from blood which comprises bringing blood that comprises infected leucocytes into contact with an adsorbent carrier that has a greater affinity for infected, activated and / or defective leucocytes than for uninfected leucocytes especially cellulose acetate. The method can be used in the apheresis treatment of diseases caused by pathogenic organisms, for example, HIV, HCV or malaria. It is especially useful for treatment of HIV.
Owner:JIMRO
Method of classifying counting leucocytes
ActiveUS20050202400A1Low costAccurate classificationMicrobiological testing/measurementChemiluminescene/bioluminescenceStainingRed blood cell
There is provided a method for classifying and counting leukocytes with abnormal DNA amount, which comprises: (1) a step of staining cells in a sample obtained from a hematological sample by treatment with a hemolytic agent to lyse erythrocytes, with a fluorescent dye which can make a difference in the fluorescence intensity at least among mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes; (2) a step of introducing the sample containing the stained cells into a flow cytometer to measure scattered light and fluorescence of the respective cells; (3) a step of classifying leukocytes and coincidence cells / platelet clumps utilizing a difference in the intensity of a scattered light peak and a difference in the scattered light width; (4) a step of classifying and counting mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes, utilizing a difference in the scattered light intensity and a difference in the fluorescence intensity of leukocytes classified in the step (3).
Owner:SYSMEX CORP
Method for determination of nucleated red blood cells and leukocytes in a whole blood sample in an automated hematology analyzer
ActiveUS20080153170A1Reduce distractionsInterfere with accurateSamplingBiological particle analysisLipid formationRed blood cell
A method for enumerating white blood cells and nucleated red blood cells. The method comprises the steps of:(b) providing a lysed sample of whole blood;(b) introducing the lysed sample to a light-scattering multi-angle depolarizing flow cytometer;(c) removing depolarizing interference, e.g., lipid droplets and other measured particles;(d) differentiating nucleated red blood cells and noise from white blood cells in the absence of depolarizing interference;(e) differentiating nucleated red blood cells from noise in the absence of depolarizing interference and white blood cells; and(f) differentiating possible platelet clumps.
Owner:ABBOTT LAB INC
Integrated microfluidic chip for capture of cancer cells in whole blood
The invention relates to an integrated microfluidic chip for capture of cancer cells in whole blood. The integrated microfluidic chip for capture of cancer cells in whole blood comprises three inlets, an erythrocyte lysis unit, a leucocyte capture unit, a cancer cell capture unit and an outlet, wherein the three inlets, the erythrocyte lysis unit, the leucocyte capture unit, the cancer cell capture unit and the outlet are connected orderly. The leucocyte capture unit comprises a first diverter, a soft magnetic microcolumn array and permanent magnets. The first diverter is connected with the soft magnetic microcolumn array. The permanent magnets are arranged at two sides of the soft magnetic microcolumn array. The cancer cell capture unit comprises a second diverter and a capture microstructure array, wherein the second diverter and the capture microstructure array are connected orderly. Compared with the prior art, the integrated microfluidic chip for capture of cancer cells in whole blood has the advantages of high integration degree, simple operation, high cell capture efficiency, simple manufacture processes and the like.
Owner:SHANGHAI JIAO TONG UNIV
Blood bag system and process for the inactivation of pathogens in platelet concentrates by use of the blood bag system
InactiveUS20100133203A1Reduction of therapeutic qualityAvoid accessDiagnosticsSurgeryWhite blood cellUltraviolet
The present invention relates to a blood bag system, a method for its manufacture, and a process for reducing pathogens and leucocytes in biological fluids in particular in therapeutic quantities of platelet concentrates (PC) contained in the blood bag system, using UV-light and agitation, wherein part of the plasma of the PC is optionally exchanged against a platelet additive solution.
Owner:MACO PHARMA SA
Differential blood count reagent, kit and method of differential blood count
ActiveCN101750274AThe classification processing effect is goodLow costMethine/polymethine dyesOrganic chemistryCyanineDifferential blood count
The invention discloses a differential blood count reagent which comprises the following components: (1) a cyanine anion compound selected form compounds expressed by the formula I or formula II, (2) an anode surfactant expressed by the formula III, IV or V and (3) at least one nonionic surfactant. The invention also discloses a kit containing the differential blood count reagent and a method of the differential blood count. By utilizing the reagent, the kit and the method, five subclasses of leucocytes can be quickly identified within a very short time, four-classification count is at least carried out, and immaturate cells and abnormal cells can be distinguished.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD
Application of ursane type triterpenoid saponin in the preparing process of leucocyte and/or platelet increasing medicine
InactiveCN1593436ASignificant effectLower doseOrganic active ingredientsBlood disorderWhite blood cellMedicine
The invention discloses the use of ursane type triterpenoid saponin in preparing medicine for increasing leucocyte and / or platelet which has a general formula (I), the invention also provides a pharmaceutical composition having the action of increasing human leucocyte and / or platelet, which contains ursane type triterpenoid saponin composition having a general formula (I), and pharmaceutically acceptable salts.
Owner:CHENGDU DIAO PHARMA GROUP
Method of classifying and counting leucocytes
ActiveUS20080176274A1Low costAccurate classificationMicrobiological testing/measurementIndividual particle analysisStainingWhite blood cell
Owner:SYSMEX CORP
Recombinant Ganoderma lucidum immunoregulation protein with antineoplastic function and medicinal preparation thereof
The invention discloses a recombinant Ganoderma Lucidum immunomodulatory protein (rLZ-8) which has anti-tumor effect and is expressed by Pichia pastoris, and a pharmaceutical preparation thereof. The rLZ-8 has the effect of directly killing or damaging NB4 or K562 or HL-60 or S180 or H22 cells and not affecting normal cells; and the rLZ-8 can quickly and efficiently induce a plurality of tumor cells to apoptosize in vitro, can also effectively kill the tumor cells in a body of a mouse tumor model, has no obvious toxic side effect, and can keep or raise the level of leucocytes. In addition, the invention also provides an anti-tumor pharmaceutical preparation type taking the rLZ-8 as a core composition.
Owner:张喜田
Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them
Substituted imidazolidine derivatives of the formula I,in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and / or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and / or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations which contain compounds of the formula I.
Owner:SANOFI AVENTIS DEUTSCHLAND GMBH
Circulating tumor cell separation micro-fluidic chip device and application method thereof
PendingCN107084916ASimple structureEasy to processIndividual particle analysisLaboratory glasswaresWhite blood cell numberEngineering
The invention relates to a circulating tumor cell separation micro-fluidic chip device and an application method thereof. The device comprises a micro-fluidic chip (1) and a chip fixture (2). The micro-fluidic chip (1) comprises a chip inlet (11), a single-screw chip (12), rare cell collection tubes (13, 14) and a leucocyte outlet (15). A single-screw channel starts from the chip inlet (11) at the center of a circular spiral channel, passes through a semicircular starting channel and enters a spiral micro-fluidic channel. The tail end contains three outlets: rare cells with different particle sizes are respectively collected; and the chip fixture (2) is automatically in butt joint with inlet and outlet of the micro-fluidic chip (1). In comparison with the prior art, the micro-fluidic chip device of the invention has the following beneficial effects: a treated sample can be automatically subjected to automated high-throughput tumor cell separation and tumor cells in a liquid sample such as peripheral blood / pleural effusion / cerebrospinal fluid, etc. of a cancer patient can be enriched; and cancer patient diagnosis and customized treatment specificity and accuracy are remarkably enhanced.
Owner:上海纳奥生物科技有限公司
Reagent for hemocyte analyzers
The invention discloses a reagent for hemocyte analyzers, which is prepared from diluent, hemolytic agent, sheath flow liquid and cleaning fluid. Compared with the prior art, the invention changes the actual state of long-term dependence on import of the reagent for hemocyte analyzers in China, and is produced and sold in China, thereby greatly reducing the production cost; the hemolytic agent in the reagent does not contain cyanogen, thereby greatly reducing the injury to health of the personnel and experiment operators in manufacturing factories, and avoiding the environment pollution of prussiates; the reagent is especially suitable for the CD3700 / 3500, CD3000 and CD3200 differential count full-automatic hemocyte analyzers of Abbott Laboratories in America, and the hemolytic agent A750test indicates the reagent achieves the ICSH standard; and the correlation coefficients of leucocyte, erythrocyte, hemoglobin, thrombocyte and the like relative to the imported ABBOTT CELL-DYN3700 / 3500 reagent are respectively greater than 0.95.
Owner:URIT MEDICAL ELECTRONICS CO LTD
Nutritive composition for accelerating hemopoietic stem cell proliferation and hemoglobin synthesis
ActiveCN101172140AIncrease the number ofOrganic active ingredientsHeavy metal active ingredientsArginineWhite blood cell
The invention discloses a nutritional composition for promoting the proliferation of hematopoietic stem cells and the synthesis of haemoglobin. The invention is characterized in that the invention comprises raw materials and the proportion by weight as follows: 90 to 110 nucleotide, 20 to 30 parts of arginine, 20 to 30 parts of lysine, 10 to 20 parts of cysteine, 25 to 35 parts of glycin, 20 to 30 parts of histidine, 110 to 130 parts of lecithin, 50 to 70 parts of cephalin, 0.4 to 0.6 parts of vitamin E, 5 to 7 vitamin C, 0.02 to 0.04 parts of folacin, 0.05 to 0.07 parts of vitamin B2, 0.07 to 0.08 vitamin B6, 0.0001 to 0.0002 parts of vitamin B12, 0.5 to 1.5 parts of ferrum, 0.5 to 0.7 parts of zinc, 0.4 to 0.6 parts of manganese, 14 to 16 parts of boxthorn amylase, and 14 to 16 parts of grapestone aqueous extract. The invention can evidently improve the quantity of hemoglobins (Hb), red blood cells (RBC), white blood cells (WBC) and blood platelets (Plt) in the blood, can stimulate the proliferation of the marrow hematopoietic stem cells to lead the hematopoietic stem cells to be evidently increased, can evidently improve the number of mitochondrion in the cell and have obvious recovery function to the damage of liver and spleen.
Owner:珍奥集团股份有限公司
Hemolytic agent, leucocyte classification reagent system and classification method
The invention relates to a hemolytic agent for a blood cell analysis device. The hemolytic agent is capable of cracking the erythrocytes in the blood, and the blood with cracked erythrocytes can be used for hemoglobin concentration determination. In addition, the invention also relates to a leukocyte classification reagent system which comprises the hemolytic agent and an inhibitor. After the hemolytic agent cracks the erythrocytes, the inhibitor can be added into the blood to prevent the hemolytic agent from damaging the morphology and structure of the leucocytes. Furthermore, the invention also relates to a method of classifying the leucocytes by using the reagent system.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD +1
Integrated Blood Specimen Processor
A blood specimen processor by means of which blood specimens are collected into a collection tube containing an anticoagulant and a molded buoy of predetermined density between 1.045 and 1.084 with an embedded water swellable o-ring that expands to form a robust seal in a leucocyte density gradient between the buoy's outer surface and tube's inner surface. The buoy is made of a first resin and a second resin, the first resin having a lower density than the second resin, the first resin and the second resin being present in such amounts and relative proportions so that the body has an overall density between 1.045 and 1.084 and preferably, a center of gravity below a geometric center of the body. When the blood specimen contained in the processor is centrifuged, the buoy is thrust through the separating blood and the developing interface of erythrocytes, leucocytes, and plasma. A reproducible gradient develops that builds a reproducible buffy coat ring around the upper trough at the junction of the edge of the separator buoy and the tube wall. The relative proportions of resin are controlled to create a separator buoy of a desired density so that after centrifugation the buffy coat or other cells of interest will be above the water swellable o-ring.
Owner:COLEMAN CHARLES M
Reagent for determination of leucocytes and measurement of haemoglobin in a sample of blood
The invention concerns a reagent for determination of leucocytes and measurement of haemoglobin in a sample of blood. This reagent comprises a buffer system that is suited to adjust selectively the pH of the reagent to an acidic value, at least one detergent of cationic type, a nitrogenous compound and, optionally, at least one inorganic salt. This reagent can be used in haematological analyses in human medicine and also permits the identification of a leucocytic subpopulation, in particular the basophil polymorphonuclear leucocytes.
Owner:HORIBA ABX SAS
Methods for diagnosing and treating tumors and suppressing cd promoters
InactiveUS20060216231A1Reduce in quantityBiocideGenetic material ingredientsAbnormal tissue growthWhite blood cell
Methods of treating tumors, reducing white blood cell numbers, and inhibiting CD promoters are provided.
Owner:THE GENERAL HOSPITAL CORP
Gene expression in peripheral blood mononuclear cells from children with diabetes
InactiveUS20080227709A1Peptide/protein ingredientsLibrary screeningPeripheral blood mononuclear cellWhite blood cell
The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Preparation for amylovorin of bacillus and application thereof
InactiveCN1908182AIncrease productionHigh yieldOrganic active ingredientsBacteria material medical ingredientsLymphocyteWhite blood cell number
the invention discloses a preparing method of extracellular polysaccharide of Bacillus subtilis and application in the tumour facet, which is characterized by the following: inhibiting tumour from growing; accelerating the growth of macrophage, leucocyte and lymph cell; fitting for health or immune adjusting drug.
Owner:NANJING UNIV
Analyzer and analyzing method
The present invention is to present a blood analyzer which can prevent an abnormal number of white blood cells caused by the lipid particles or the red blood cells of poor hemolysis from being output. The blood analyzer comprises: first white blood cell number obtaining means; second white blood cell number obtaining means; output means for outputting the number of the white blood cells obtained by the second white blood cell number obtaining means, and determining means for determining whether the number of the white blood cells obtained by the second white blood cell number obtaining means is abnormal, wherein the output means is configured to output the number of the white blood cells obtained by the first white blood cell number obtaining means when the determining means determines that the number of the white blood cells obtained by the second white blood cell number obtaining means is abnormal.
Owner:SYSMEX CORP
Microfluidic device and leucocyte antigen mediated microfluidic assay
ActiveUS20090011451A1Easy to doMicrobiological testing/measurementBiological material analysisCellular antigensWhite blood cell
Owner:ADVANCED ANIMAL DIAGNOSTICS
Immune cell microfluid array
InactiveCN1403817AImprove the efficiency of differentiation antigen detectionMicrobiological testing/measurementBiological testingAntigenWhite blood cell
The present invention relates to one kind of immune cell microfluid array belonging to the field of cell immunity test technology. On the polymer substrate of the immune cell microfluid array, there are orderly arranged pores communicated via inclined micro tubes. By using the present invention, once operation can detect cell with corresponding leucocyte differentiating antigen, and thus judges the kind of leucocyte differentiating antigen and the growth and decline rule of the leucocyte differentiating antigen. The present invention results in high working efficiency.
Owner:中国人民解放军南京军区联勤部军事医学研究所
Electrocerebral non-linear dual-measure feature extraction and fusion processing method
InactiveCN103767702AImprove classification accuracyDiagnostic recording/measuringSensorsSvm classifierCrowds
The invention discloses an electrocerebral non-linear dual-measure feature extraction and fusion processing method, and relates to the field of electrocerebral signals. The method comprises the following steps: acquiring an electrocerebral signal; performing data preprocessing on the electrocerebral signal; extracting an LZC (Leucocyte Zinc Content) complexity feature from preprocessed data; extracting a sample entropy feature, and performing feature analysis on the LZC complexity feature and the sample entropy feature; establishing a classification model with an SVM (Support Vector Machine) classifier by jointly taking the LZC value of the electrocerebral signal and a sample entropy value which are remarkably different as a feature parameter in order to classify and identify people in different psychological states. By adopting the method for classifying and identifying the electrocerebral signals of people in different psychological states, higher classifying accuracy can be achieved, and an objective evaluation index can be provided for the partition of people in different psychological states.
Owner:TIANJIN UNIV
Method for eliminating HIV in human blood and a device for treating AIDS with non-pharmacotherapy
InactiveUS7220236B2Safe and easy operationCost effectiveOther blood circulation devicesMedical devicesUltravioletLymphocyte
The invention provides a method for eliminating HIV in human blood and a device for treating AIDS with non-pharmacotherapy. The method includes (1) pumping the blood containing HIV virus into a soft thin plastic tube while adding air through a T-tube at a definite frequency so that the blood is evenly divided into very small blood droplets (2) introducing the small blood droplets into a screw-shaped quartz tube and exposing the quartz tube under a definite dosage of radiation to kill the HIV virus in the blood droplets is (3) collecting the treated blood in a storage bottle. Results show that after the HIV infected blood is divided into very small blood droplets and is irradiated with a definite dosage of ultraviolet (253.7 nm) for 90 seconds, more than 92% HIV loads in the blood is eliminated, while the lymphocyte (CD4+), erythrocyte, leucocyte and haemoglobin remain almost unchanged.
Owner:RES CENT FOR ECO ENVIRONMENTAL SCI THE CHINESE ACAD OF SCI
Circulating tumor cell separation device adopting combined field flow separation
ActiveCN105647799AHigh selectivityProcessing speedBiological substance pretreatmentsStress based microorganism growth stimulationTherapy monitoringDisease
The invention provides a circulating tumor cell separation device adopting combined field flow separation. The circulating tumor cell separation device comprises an upper cover plate, a channel plate and a substrate plate from top to bottom; a two-step separation method comprising the field flow separation and specific molecular affinity identification is adopted, wherein the field flow separation adopts an acoustic surface wave driving mode and a dielectrophoresis driving mode, horizontal cell grouping migration and cell layering in a vertical plane are realized respectively, and erythrocytes are preliminarily separated from other cell populations; a residual leucocyte mixed liquid passes through a cell recognition area, circulating tumor cells are fixed in the recognition area by recognition ligands, and a tumor cell sample is acquired through releasing operation finally. The device can rapidly realize circulating tumor cell separation without marks, has great significance in the aspects of patient's disease diagnosis, therapy monitoring, pathological research and the like, and can be used for a separation process of other cells, macromolecular protein and micro-particles.
Owner:上海揽微赛尔生物科技有限公司
Thrombocyte sampling device
A platelet collecting apparatus 1 comprises a centrifugal separator 20 possessing a rotatable rotor 142 ; a first line 21 for allowing the flow of the blood entering the centrifugal separator 20; a second line 22 for allowing the flow of the blood emanating from the centrifugal separator, a plasma collecting bag 25 connected to the first line 21 and the second line 22 so as to collect the plasma emanating from the centrifugal separator 20 and return the collected plasma to the centrifugal separator 20, a platelet collecting bag 26 connected to the second line 22 so as to collect the platelets emanating from the centrifugal separator 20, a blood delivering pump 11 disposed in the first line 21, and a controller 13 for controlling the operation of the rotor of the centrifugal separator 20 and the operation of the blood delivering pump 11. The controller 13 is endowedwith a function of varying the rotational frequency of the rotor 142 during the course of blood collection in conformity with the amount of the blood entered into the centrifugal separator 20 via the first line 21. The invention provides a platelet collecting device with minimal inclusion of leucocyte and having high sampling efficiency of platelet.
Owner:TERUMO KK
Erythrocyte lysis buffer and application thereof
InactiveCN103789298AHigh purityReduce manufacturing costDNA preparationWhite blood cellWhite blood cell number
The invention provides an erythrocyte lysis buffer. The erythrocyte lysis buffer comprises the following components: 4.5-5.5 mmol / L of sodium chloride, 0.8-1.3% (v / v) of triton 100, 300-340mmol / L of glucose and 0.008-0.012 mol / L of trishydroxymethyl aminomethane. The erythrocyte lysis buffer can effectively lyse the erythrocyte in a whole blood sample, separate and enrich leucocyte in the blood, and facilitate the subsequent nucleic acid extraction operation of the leucocyte, so as to obtain the leucocyte DNA in the whole blood sample and the DNA of virus in the leucocyte.
Owner:SANSURE BIOTECH INC
Blood smear self-focusing microimaging method
InactiveCN106990518AImprove efficiencyRaise the bar for quality outputMicroscopesMotor driveWhite blood cell
The invention discloses a blood smear self-focusing microimaging method, which comprises an objective table for holding a blood smear, a focusing motor for driving the objective table to move, and a shooting device for shooting blood smear pictures in the moving process of the objective table. The method comprises the following steps: S1) the blood smear is prepared and placed on the objective table, wherein the objective table locates at a focusing start point; S2) the focusing motor drives the objective table to move to a focusing end point at a first preset speed; S3) in the moving process of the objective table in the step S2), the shooting device shoots the blood smear pictures with a preset frequency and records the shooting position; and S4) the obtained pictures are subjected to processing through a focusing evaluation function, and the position where a focal plane locates is obtained through the processed pictures to obtain clear imaging of leucocytes in the blood smear. The pictures shot by the shooting device are processed through the focusing evaluation function, and imaging of the blood smear is obtained according to the processed images, so that focusing can be realized without labor, and manpower and material resources are saved.
Owner:SHENZHEN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com